# Optimal Duration of Anticoagulation in Deep Venous Thrombosis

Study · id `cardio:ct-nct01285661` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01285661](<https://clinicaltrials.gov/study/NCT01285661>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01285661

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 584 participants.

## Technical summary

Registry record NCT01285661. Allocation not applicable; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 584 participants (enrolled count; ClinicalTrials.gov record NCT01285661, source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)
- Start date: 2010-03 (registry gives no type) (ClinicalTrials.gov record NCT01285661, source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)
- Primary completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01285661, source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01285661, source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT01285661, source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01285661-2016-07-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Optimal Duration of Anticoagulation in Deep Venous Thrombosis
- Acronym: MORGAGNI
- Condition: Deep Vein Thrombosis of Lower Limb
- Condition: Lower Extremity Deep Venous Thrombosis Recurrent
- Intervention (Drug): Sodium warfarin
- Lead sponsor: University of Padova
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: University of Padova (`cardio:org-university-of-padova`)

## Provenance

Content hash: 62375d9c751425c3f862050940e08ddbb6667c32e4642abdd1daaea3a8c89303
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
